Australia - English - Department of Health (Therapeutic Goods Administration)

immunoglobulin g - human; immunoglobulin - hepatitis b; hepatitis b immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - immunoglobulin - normal; normal immunoglobulin; normal immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - immunoglobulin - normal; normal immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

immunoglobulin - anti-d rho; human anti-d rho immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

immunoglobulin g - human; immunoglobulin - tetanus; tetanus immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

immunoglobulin g - human; immunoglobulin - zoster; zoster immunoglobulin -

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - anti-d [rho] immunoglobulin 250 [iu] - solution for injection - 250 iu - active: anti-d [rho] immunoglobulin 250 [iu] - rh(d) immunoglobulin-vf is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - anti-d [rho] immunoglobulin 625 [iu] - solution for injection - 625 iu - active: anti-d [rho] immunoglobulin 625 [iu] excipient: glycine water for injection - rh(d) immunoglobulin-vf is indicated for the prevention of rh sensitisation in rh(d) negative females at or below child bearing age.

Israel - English - Ministry of Health

kamada ltd, israel - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 50 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, and children and adolescents (0-18 years) in:- primary immunodeficiency syndromes (pid) with impaired antibody production- secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of <4 g/l* psaf= failure to mount at least a 2-fold rise in igg antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccinesimmunomodulation in adults, and children and adolescents (0-18 years) in:- primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count- guillain barré syndrome- kawasaki disease (in conjunction with acetylsalicylic acid)- chronic inflammatory demyelinating polyradiculoneuropathy (cidp)- multifocal motor neuropathy (mmn)

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human plasma protein >90% gamma globulin - solution for injection - 1.6g/10ml %w/v